469 related articles for article (PubMed ID: 33838223)
1. The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
Clerici D; Oltolini C; Greco R; Ripa M; Giglio F; Mastaglio S; Lorentino F; Pavesi F; Farina F; Liberatore C; Castiglion B; Tassan Din C; Bernardi M; Corti C; Peccatori J; Scarpellini P; Ciceri F; Castagna A
Int J Antimicrob Agents; 2021 Jun; 57(6):106335. PubMed ID: 33838223
[TBL] [Abstract][Full Text] [Related]
2. Rectal culture could predict carbapenem-resistant organism bloodstream infection and reduce the mortality in haematological patients: A retrospective cohort study.
Gao S; Yan R; Zhang S; Li L; Zhang R; Fan J; Qin J; Peng Y; Wan D; Cao W; Bian Z
J Glob Antimicrob Resist; 2024 Mar; 36():96-104. PubMed ID: 38128727
[TBL] [Abstract][Full Text] [Related]
3. Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience.
Meschiari M; Faltoni M; Kaleci S; Tassoni G; Orlando G; Franceschini E; Burastero G; Bedini A; Serio L; Biagioni E; Melegari G; Venturelli C; Sarti M; Bertellini E; Girardis M; Mussini C
Int J Antimicrob Agents; 2024 May; 63(5):107134. PubMed ID: 38453094
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Resistant Gram-Negative Bacilli in Bloodstream Infection in Febrile Neutropenia Patients Undergoing Hematopoietic Stem Cell Transplantation: A Single Center Retrospective Cohort Study.
Wang L; Wang Y; Fan X; Tang W; Hu J
Medicine (Baltimore); 2015 Nov; 94(45):e1931. PubMed ID: 26559260
[TBL] [Abstract][Full Text] [Related]
5. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
Liscio JL; Mahoney MV; Hirsch EB
Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
[TBL] [Abstract][Full Text] [Related]
6. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
[TBL] [Abstract][Full Text] [Related]
7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
8. Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis.
Gatti M; Raschi E; De Ponti F
Eur J Clin Microbiol Infect Dis; 2021 Jun; 40(6):1169-1176. PubMed ID: 33415492
[TBL] [Abstract][Full Text] [Related]
9. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
10. Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
Meschiari M; Asquier-Khati A; Tiseo G; Luque-Paz D; Murri R; Boutoille D; Falcone M; Mussini C; Tattevin P;
Int J Antimicrob Agents; 2024 Jul; 64(1):107186. PubMed ID: 38688353
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes and risk factors for mortality in recipients with carbapenem-resistant gram-negative bacilli infections after kidney transplantation treated with ceftazidime-avibactam: a retrospective study.
Zhang F; Li P; Zhong J; Ding H; Liao G; Liang C
Front Cell Infect Microbiol; 2024; 14():1404404. PubMed ID: 38779560
[TBL] [Abstract][Full Text] [Related]
12. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital.
Poon LM; Jin J; Chee YL; Ding Y; Lee YM; Chng WJ; Chai LY; Tan LK; Hsu LY
Singapore Med J; 2012 Nov; 53(11):720-5. PubMed ID: 23192498
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB.
Clerici D; Galli L; Greco R; Lugli AP; Erbella F; Ripa M; Tassan Din C; Nitti R; Giglio F; Mastaglio S; Lorentino F; Xue E; Farina F; Liberatore C; Poli A; Carletti S; Lupo Stanghellini MT; Carrabba MG; Assanelli AA; Ruggeri A; Bernardi M; Corti C; Peccatori J; Mancini N; Scarpellini P; Ciceri F; Castagna A; Oltolini C
Blood Adv; 2023 May; 7(9):1621-1634. PubMed ID: 36409602
[TBL] [Abstract][Full Text] [Related]
15. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children.
Rodriguez BA; Girotto JE; Nicolau DP
Curr Pediatr Rev; 2018; 14(2):97-109. PubMed ID: 29521242
[TBL] [Abstract][Full Text] [Related]
16. Ceftolozane/tazobactam and ceftazidime/avibactam antimicrobial activity against clinically relevant gram-negative bacilli isolated in Mexico.
Martínez-Miranda R; Gastélum-Acosta M; Guerrero-Estrada P; Ayala-Figueroa RI; Osuna-Álvarez LE
Gac Med Mex; 2020; 156(6):592-597. PubMed ID: 33877120
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI).
Kongnakorn T; Eckmann C; Bassetti M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
Antimicrob Resist Infect Control; 2019; 8():204. PubMed ID: 31890160
[TBL] [Abstract][Full Text] [Related]
18. Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients.
Balandín B; Ballesteros D; Pintado V; Soriano-Cuesta C; Cid-Tovar I; Sancho-González M; Pérez-Pedrero MJ; Chicot M; Asensio-Martín MJ; Silva JA; de Luna RR; Gesso CM; Rodríguez-Serrano DA; Martínez-Sagasti F; Royuela A
Int J Antimicrob Agents; 2022 Mar; 59(3):106536. PubMed ID: 35091054
[TBL] [Abstract][Full Text] [Related]
19. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
Scudeller L; Righi E; Chiamenti M; Bragantini D; Menchinelli G; Cattaneo P; Giske CG; Lodise T; Sanguinetti M; Piddock LJV; Franceschi F; Ellis S; Carrara E; Savoldi A; Tacconelli E
Int J Antimicrob Agents; 2021 May; 57(5):106344. PubMed ID: 33857539
[TBL] [Abstract][Full Text] [Related]
20. Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection.
Xie O; Cisera K; Taylor L; Hughes C; Rogers B
Ann Clin Microbiol Antimicrob; 2020 Nov; 19(1):57. PubMed ID: 33256752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
